Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Helps Predict Stomach Cancer Survival

By LabMedica International staff writers
Posted on 16 Sep 2015
A biomarker has been identified in patients with stomach cancer that starves tumors of their blood supply and reduces the ability of cancer cells to spread to other parts of the body. More...


In the USA, stomach cancer, also known as gastric cancer, most commonly affects older people, as around 60% of those diagnosed each year are over 65. Stomach cancer is most common in less developed countries, and it is a primary cause of cancer-related deaths worldwide.

Scientists at the Southern Medical University (Guangzhou, China) used a form of genetic analysis called quantitative real-time polymerase chain reaction (qRT-PCR) to detect micro ribonucleic acid 506 (miR-506) in human gastric samples taken from 84 people who had undergone cancer surgery. The team analyzed the miR-506 levels in each of these samples, and patients were allocated to different groups based on whether they were above or below the mean miR-506 level.

They found that miR-506 expression was a useful marker for stratifying patients from early to advanced clinical stages and for overall survival prediction. Overexpression of miR-506 inhibited the epithelial-to-mesenchymal transition of gastric cancer cells; however, depletion of miR-506 promoted it. In addition, miR-506 suppressed gastric cancer angiogenesis and was associated with decreased matrix metalloproteinase-9 expression. They also found that V-Ets Avian Erythroblastosis virus E26 Oncogene Homolog 1 (ETS1) was a miR-506 target, and it was expressed in 71.10% of gastric cancer tissue samples. At 60 months, cumulative survival was approximately 30% in the low-miR-506 expression group, compared with 80% in the high-expression group.

The team then looked at signs of miR-506 in seven stomach cancer cell lines. Here, it was found that stomach cancer cells had lower levels of miR-506 than normal stomach tissue. Analysis of cells grown in vitro then showed that miR-506 levels were lowest in the cell lines that had the highest invasive activity, and the highest levels were seen in cell lines with the lowest invasive activity.

Xin Song, MD, PhD, the lead investigator, said, “Our findings indicate that miR-506 is necessary and sufficient for angiogenesis suppression during gastric cancer progression. Cancer is a complex disease and controlling cancer development and progression requires system level and integrative approaches. Our study suggests that miR-506 acts as a tumor suppressor in gastric cancer." The study was published on September 8, 2015, in the American Journal of Pathology.

Related Links:

Southern Medical University 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Slide Scanner System
NanoZoomer S540MD
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.